nvestors treat them as a direct hit to a company’s future product lineup, trimming expected revenue years in advance. Other headlines were more idiosyncratic: Prenetics Global, a genetic testing company, dropped 8.7% after a wider quarterly loss, while Johnson & Johnson, a US healthcare conglomerate, edged up 0.7% even after a Los Angeles jury ordered it to pay $32 million in an asbestos-contaminated talc case, according to the family’s law firm.
Why should I care?
For markets: Sanofi’s halted riliprubart phase 3 helps explain the biotech ETF’s 1.8% slide.
When a company stops a phase 3 trial because the odds of showing enough efficacy look low, markets aren’t just reacting to a bad headline – they’re rewriting the math on the drug’s potential cash flows. A late-stage asset sits close to commercialization, so a “futility” stop can wipe out a large chunk of that program’s expected value quickly, rather than gradually. That pipeline repricing is also why investors often demand a higher uncertainty premium across biotech when big readouts disappoint, pushing the group down more than broader healthcare – like the iShares Biotechnology ETF’s 1.8% drop versus the NYSE Healthcare Index’s 0.8% dip.